The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model

Leukemia

Volumn 28, Issue 7, 2014, Pages 1501-1510

  Beckwith, K A ^a   Frissora, F W ^a   Stefanovski, M R ^a   Towns, W H ^a   Cheney, C ^a   Mo, X ^a   Deckert, J ^b   Croce, C M ^a   Flynn, J M ^a   Andritsos, L A ^a   Jones, J A ^a   Maddocks, K J ^a   Lozanski, G ^a   Byrd, J C ^a   Muthusamy, N ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b IMMUNOGEN INC   (United States)

Author keywords

antibody drug conjugate; CD37; chronic lymphocytic leukemia

Indexed keywords

ALEMTUZUMAB; ANTILEUKEMIC AGENT; CD37 ANTIGEN; IMGN 529; K 7153A; MONOCLONAL ANTIBODY; OFATUMUMAB; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; B LYMPHOCYTE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTOSIS; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; APOPTOSIS; B-LYMPHOCYTES; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; IMMUNITY, INNATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE DEPLETION; MICE; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; TETRASPANINS;

EID: 84904071256     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.32     Document Type: Article

References (36)

1. Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005 105 49-53.
2. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 2011 117 3016-3024.
3. Plosker GL, Figgitt DP. Rituximab a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003 63 803-843.
4. Woyach JA, Ruppert AS, Heerema NA, Peterson BL, Gribben JG, Morrison VA et al. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia long-term follow-up of CALGB study 9712. J Clin Oncol 2011 29 1349-1355.
5. Rezvani AR, Maloney DG. Rituximab resistance. Best Pract Res Clin Haematol 2011 24 203-216.
6. Link MP, Bindl J, Meeker TC, Carswell C, Doss CA, Warnke RA et al. A unique antigen on mature B-cells defined by a monoclonal antibody. J Immunol 1986 137 3013-3018.
7. Schwartz-Albiez R, Dorken B, Hofmann W, Moldenhauer G. The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein. J Immunol 1988 140 905-914.
8. Lapalombella R, Yeh YY, Wang L, Ramanunni A, Rafiq S, Jha S et al. Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell 2012 21 694-708.
9. van Spriel AB, de Keijzer S, van der Schaaf A, Gartlan KH, Sofi M, Light A et al. The tetraspanin CD37 orchestrates the alpha(4)beta(1) integrin-Akt signaling axis and supports long-lived plasma cell survival. Sci Signal 2012 5 ra82.
10. Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 2007 110 2569-2577.
11. Heider KH, Kiefer K, Zenz T, Volden M, Stilgenbauer S, Ostermann E et al. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood 2011 118 4159-4168.
12. Krause G, Patz M, Isaeva P, Wigger M, Baki I, Vondey V et al. Action of novel CD37 antibodies on chronic lymphocytic leukemia cells. Leukemia 2012 26 546-549.
13. Deckert J, Park PU, Chicklas S, Yi Y, Li M, Lai KC et al. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood 2013 122 3500-3510.
14. Oroudjev E, Lopus M, Wilson L, Audette C, Provenzano C, Erickson H et al. Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther 2010 9 2700-2713.
15. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012 367 1783-1791.
16. de Claro RA, McGinn K, Kwitkowski V, Bullock J, Khandelwal A, Habtemariam B et al. U.S. Food and Drug Administration approval summary brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 2012 18 5845-5849.
17. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B-cells. J Clin Invest 2005 115 755-764.
18. Chiorazzi N. Cell proliferation and death forgotten features of chronic lymphocytic leukemia B-cells. Best Pract Res Clin Haematol 2007 20 399-413.
19. Caligaris-Cappio F. Role of the microenvironment in chronic lymphocytic leukaemia. Br J Haematol 2003 123 380-388.
20. Soma LA, Craig FE, Swerdlow SH. The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma. Hum Pathol 2006 37 152-159.
21. Caligaris-Cappio F, Ghia P. Novel insights in chronic lymphocytic leukemia are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol 2008 26 4497-4503.
22. Vandewoestyne ML, Pede VC, Lambein KY, Dhaenens MF, Offner FC, Praet MM et al. Laser microdissection for the assessment of the clonal relationship between chronic lymphocytic leukemia/small lymphocytic lymphoma and proliferating B-cells within lymph node pseudofollicles. Leukemia 2011 25 883-888.
23. Broyde A, Boycov O, Strenov Y, Okon E, Shpilberg O, Bairey O. Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma. Am J Hematol 2009 84 338-343.
24. Chen HC, Byrd JC, Muthusamy N. Differential role for cyclic AMP response element binding protein-1 in multiple stages of B cell development, differentiation, and survival. J Immunol 2006 176 2208-2218.
25. Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 2002 99 6955-6960.
26. Johnson AJ, Lucas DM, Muthusamy N, Smith LL, Edwards RB, De Lay MD et al. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood 2006 108 1334-1338.
27. Vugmeyster Y, Howell K, Bakshl A, Flores C, Canova-Davis E. Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B-cells in a whole blood matrix. Cytometry A 2003 52 101-109.
28. Yan XJ, Albesiano E, Zanesi N, Yancopoulos S, Sawyer A, Romano E et al. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2006 103 11713-11718.
29. Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008 118 2427-2437.
30. Chen SS, Raval A, Johnson AJ, Hertlein E, Liu TH, Jin VX et al. Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2009 106 13433-13438.
31. Macor P, Secco E, Zorzet S, Tripodo C, Celeghini C, Tedesco F. An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies. Curr Pharm Des 2008 14 2023-2039.
32. Shimoni A, Marcus H, Canaan A, Ergas D, David M, Berrebi A et al. A model for human B-chronic lymphocytic leukemia in human/mouse radiation chimera evidence for tumor-mediated suppression of antibody production in low-stage disease. Blood 1997 89 2210-2218.
33. Durig J, Ebeling P, Grabellus F, Sorg UR, Mollmann M, Schutt P et al. A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease. Cancer Res 2007 67 8653-8661.
34. Barrena S, Almeida J, Yunta M, Lopez A, Fernandez-Mosteirin N, Giralt M et al. Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia 2005 19 1376-1383.
35. Lucas DM, Edwards RB, Lozanski G, West DA, Shin JD, Vargo MA et al. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood 2009 113 4656-4666.
36. Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood 2012 120 4621-4634.